Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentation
Bitget2026/09/23 20:06- Mineralys Therapeutics flagged new long-term efficacy and safety findings from its Transform-HTN open-label extension trial of lorundrostat.
- Results have not been presented yet; they are slated for a late-breaking session at American Heart Association Scientific Sessions 2026.
- The update supports the drug’s sustained blood-pressure control profile in uncontrolled hypertension, with safety remaining consistent over longer treatment.
- Presentation is scheduled for Nov. 8 in Chicago, positioning lorundrostat for higher visibility with clinicians and investors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
